Eli Lilly Option Alert: Nov 7 $800 Calls Sweep (14) near the midpoint: 130 vs 331 OI; Earnings 10/30 Before Open 

Eli Lilly Option Alert: Nov 7 $800 Calls Sweep (14) near the midpoint: 130 @ $40.432 vs 331 OI; Earnings 10/30 Before Open Ref=$818.39

Eli Lilly Option Alert: Sep 18 $600 Calls Sweep (3) near the Ask: 41 vs 511 OI; Earnings 10/30 Before Open 

Eli Lilly Option Alert: Sep 18 $600 Calls Sweep (3) near the Ask: 41 @ $252.0 vs 511 OI; Earnings 10/30 Before Open Ref=$813.43

Eli Lilly Option Alert: Sep 18 $600 Calls at the Bid: 20 vs 511 OI; Earnings 10/30 Before Open 

Eli Lilly Option Alert: Sep 18 $600 Calls at the Bid: 20 @ $252.45 vs 511 OI; Earnings 10/30 Before Open Ref=$813.97

Eli Lilly Option Alert: Sep 18 $600 Calls Sweep (7) near the Bid: 80 vs 511 OI; Earnings 10/30 Before Open 

Eli Lilly Option Alert: Sep 18 $600 Calls Sweep (7) near the Bid: 80 @ $251.5 vs 511 OI; Earnings 10/30 Before Open Ref=$813.97

Eli Lilly Option Alert: Sep 18 $600 Calls at the Bid: 80 vs 511 OI; Earnings 10/30 Before Open 

Eli Lilly Option Alert: Sep 18 $600 Calls at the Bid: 80 @ $251.05 vs 511 OI; Earnings 10/30 Before Open Ref=$813.755

Eli Lilly Option Alert: Sep 18 $600 Calls at the Bid: 20 @ $251.0 vs 511 OI; Earnings 10/30 Before Open Ref=$814.065

Eli Lilly Option Alert: Sep 18 $600 Calls at the Ask: 24 vs 511 OI; Earnings 10/30 Before Open 

Eli Lilly Option Alert: Sep 18 $600 Calls at the Ask: 24 @ $245.0 vs 511 OI; Earnings 10/30 Before Open Ref=$807.23

Eli Lilly Option Alert: Sep 18 $600 Calls at the Bid: 100 vs 511 OI; Earnings 10/30 Before Open 

Eli Lilly Option Alert: Sep 18 $600 Calls at the Bid: 100 @ $238.0 vs 511 OI; Earnings 10/30 Before Open Ref=$796.74

Eli Lilly Option Alert: Nov 21 $650 Calls at the Bid: 68 vs 273 OI; Earnings 10/30 Before Open 

Eli Lilly Option Alert: Nov 21 $650 Calls at the Bid: 68 @ $155.75 vs 273 OI; Earnings 10/30 Before Open Ref=$803.03

Eli Lilly Option Alert: Sep 18 $970 Puts Sweep (14) near the midpoint: 38 vs 0 OI; Earnings 10/30 Before Open 

Eli Lilly Option Alert: Sep 18 $970 Puts Sweep (14) near the midpoint: 38 @ $202.343 vs 0 OI; Earnings 10/30 Before Open Ref=$801.42

Eli Lilly Option Alert: Sep 18 $600 Calls at the Bid: 40 vs 447 OI; Earnings 10/30 Before Open 

Eli Lilly Option Alert: Sep 18 $600 Calls at the Bid: 40 @ $242.0 vs 447 OI; Earnings 10/30 Before Open Ref=$801.61

Eli Lilly Option Alert: Sep 18 $600 Calls at the Bid: 60 vs 447 OI; Earnings 10/30 Before Open 

Eli Lilly Option Alert: Sep 18 $600 Calls at the Bid: 60 @ $242.0 vs 447 OI; Earnings 10/30 Before Open Ref=$801.39

Eli Lilly Option Alert: Oct 31 $770 Calls at the Bid: 286 vs 1087 OI; Earnings 10/30 Before Open 

Eli Lilly Option Alert: Oct 31 $770 Calls at the Bid: 286 @ $50.95 vs 1087 OI; Earnings 10/30 Before Open Ref=$803.08

Eli Lilly Option Alert: Oct 31 $810 Calls at the Bid: 286 vs 73 OI; Earnings 10/30 Before Open 

Eli Lilly Option Alert: Oct 31 $810 Calls at the Bid: 286 @ $28.15 vs 73 OI; Earnings 10/30 Before Open Ref=$803.08

Eli Lilly Option Alert: Fri $775 Calls at the Bid: 300 vs 640 OI; Earnings 10/30 Before Open 

Eli Lilly Option Alert: Fri $775 Calls at the Bid: 300 @ $25.0 vs 640 OI; Earnings 10/30 Before Open Ref=$801.2797

Eli Lilly Option Alert: Dec 19 $220 Calls at the Bid: 10 vs 125 OI; Earnings 10/30 Before Open 

Eli Lilly Option Alert: Dec 19 $220 Calls at the Bid: 10 @ $575.93 vs 125 OI; Earnings 10/30 Before Open Ref=$794.569

Eli Lilly Option Alert: Sep, 2026 $600 Calls at the Bid: 54 vs 372 OI; Earnings 10/30 Before Open 

Eli Lilly Option Alert: Sep, 2026 $600 Calls at the Bid: 54 @ $238.0 vs 372 OI; Earnings 10/30 Before Open Ref=$795.05

Eli Lilly Option Alert: Sep, 2026 $700 Calls Sweep (15) near the Ask: 50 vs 337 OI; Earnings 10/30 Before Open 

Eli Lilly Option Alert: Sep, 2026 $700 Calls Sweep (15) near the Ask: 50 @ $170.0 vs 337 OI; Earnings 10/30 Before Open Ref=$796.24

Eli Lilly

ELI LILLY & CO

Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.

Eli Lilly and Co

Tidal Trust II Defiance Daily Target 2X Long LLY ETF

Liberty Media Corporation - Series C Liberty Live Common Stock

Liberty Live Group

Liberty Media Corporation - Series A Liberty Live Common Stock

Defiance Daily Target 2X Short LLY ETF

LIBERTY LIVE SERIES B by Liberty Media Corporation

Press Releases

Lilly opens newest Gateway Labs site in San Diego to boost local biotechnology ecosystem

Lilly's Omvoh (mirikizumab-mrkz) is the first and only IL-23p19 antagonist to show four years of sustained, corticosteroid-free comprehensive patient outcomes in ulcerative colitis

Lilly to present new clinical data for Verzenio (abemaciclib) and multiple novel pipeline programs at the 2025 European Society for Medical Oncology (ESMO) Annual Meeting

Lilly's oral GLP-1, orforglipron, demonstrated superior glycemic control in two successful Phase 3 trials, reconfirming its potential as a foundational treatment in type 2 diabetes

Lilly confirms date and conference call for third-quarter 2025 financial results announcement

Lilly's Verzenio® (abemaciclib) prolonged survival in HR+, HER2-, high-risk early breast cancer with two years of treatment

Personal Finance

Big Pharma Just Put Peptides Back on the Map – Which Players Are Still Under the Radar?

Lilly's baricitinib delivered near-complete scalp hair regrowth at one year for adolescents with severe alopecia areata in Phase 3 BRAVE-AA-PEDS trial

Lilly's EBGLYSS (lebrikizumab-lbkz) delivered durable disease control when administered once every eight weeks in patients with moderate-to-severe atopic dermatitis

Lilly to Acquire Adverum Biotechnologies

ADVM

ENTX

INCY

PTGX

Amneal Pharmaceuticals, Inc. - Class A Common Stock

Amneal Pharmaceuticals

Axsome Therapeutics

AstraZeneca PLC - American Depositary Shares

AstraZeneca

Belite Bio, Inc - American Depositary Shares

Belite Bio

Bristol-Myers Squibb Company Common Stock

Bristol-Myers Squibb

Corcept Therapeutics Incorporated - Common Stock

Corcept Therapeutics

Crinetics Pharmaceuticals, Inc. - Common Stock

Crinetics Pharmaceuticals

Elanco Animal Health Incorporated Common Stock

Elanco Animal Health

GSK plc American Depositary Shares (Each representing two Ordinary Shares)

Haleon plc American Depositary Shares (Each representing two Ordinary Shares)

Haleon

Jazz Pharmaceuticals plc - Ordinary Shares

Jazz Pharmaceuticals

Johnson & Johnson

Ligand Pharmaceuticals Incorporated - Common Stock

Ligand Pharmaceuticals

Merck & Co

Novo Nordisk

Novartis

Pfizer

Dr. Reddy's Laboratories Ltd Common Stock

Dr Reddy's Laboratories

Regencell Bioscience Holdings Limited - Ordinary Shares

Regencell Bioscience

Royalty Pharma plc - Class A Ordinary Shares

Royalty Pharma

Sanofi

Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)

Takeda Pharmaceutical Co

Teva Pharmaceutical Industries Limited American Depositary Shares

Teva Pharmaceutical Indus

Viatris

Zoetis

Guggenheim

Morgan Stanley

Berenberg

JP Morgan

HSBC

Screenshot 2025-07-08 at 5.24.00 PM

News

ADBE

SBC Medical Group In Growth Mode: Company Gets Added To The Russell 3000 Index, Names New Chief Marketing Officer

Untitled design - 2025-03-31T165341.547

Biotech

General

TNXP

VRTX

Tonix&#39;s Experimental Non-Opioid Analgesic Treatment For Fibromyalgia Could Start Bringing Relief Later This Year

Screenshot 2025-02-24 at 11.35.34 PM

BRTX

BioRestorative Therapies Receives FDA Fast Track Approval For BRTX-100 To Treat Chronic Lumbar Disc Disease

Screenshot 2024-11-20 at 6.30.30 PM

BioRestorative Ends Q3 In &#39;Strong&#39; Financial Position, Reports Positive Data For Its Phase 2 BRTX-100 Chronic Back Pain Trial

Screenshot 2024-09-30 at 9.13.36 PM

The Rush For Non-Addictive Painkillers To Counter The Opioid Crisis Puts Two Companies Closer To FDA Decisions

Screenshot 2024-09-10 at 4.29.40 PM

Armed With Its Patent Portfolio, BioRestorative Therapies Has Success In The Laboratory And At The Negotiating Table: Is Profitability Close Behind?

Screenshot 2024-08-22 at 5.32.58 PM

RDHL

RedHill&#39;s Opaganib Shows Diabetes And Obesity Potential With Positive In Vivo Results

Screenshot 2024-07-10 at 9.08.28 PM

AXSM

A Redux Of The Lyrica-Cymbalta Fibromyalgia War Of The 2010s May Look More Like David Vs. Goliath

Screenshot 2024-06-18 at 1.15.14 AM

BioRestorative Therapies Enters Preclinical Assessment Of Its Patented Stem-Cell Technology Prior To First-In-Human Studies

Screenshot 2024-05-16 at 5.52.00 PM

ELAB

Elevai Labs (NASDAQ: ELAB) Acquires Rights To Develop Muscle Loss Prevention Assets For Anticipated Use In Anti-Obesity Treatments, Launches Two New Subsidiaries

Date	Put/Call	Strike Price	Exp Date	DTE	Trade Vol	Day Vol	Vol / OI	OI	Trade Type	Sentiment
09:38 AMOct 24, 2025	CALL	$800.00	Nov 07, 2025	13	130	130	39	331	SWEEP	NEUTRAL
01:00 PMOct 22, 2025	CALL	$600.00	Sep 18, 2026	328	379	41	74	511	SWEEP	BULLISH
12:54 PMOct 22, 2025	CALL	$600.00	Sep 18, 2026	328	338	20	66	511	TRADE	BEARISH
12:54 PMOct 22, 2025	CALL	$600.00	Sep 18, 2026	328	318	80	62	511	SWEEP	BEARISH
12:53 PMOct 22, 2025	CALL	$600.00	Sep 18, 2026	328	238	80	47	511	TRADE	BEARISH
12:53 PMOct 22, 2025	CALL	$600.00	Sep 18, 2026	328	158	20	31	511	TRADE	NEUTRAL
10:43 AMOct 22, 2025	CALL	$600.00	Sep 18, 2026	328	135	24	26	511	TRADE	BULLISH
09:36 AMOct 22, 2025	CALL	$600.00	Sep 18, 2026	328	100	100	20	511	TRADE	BEARISH
03:54 PMOct 21, 2025	CALL	$650.00	Nov 21, 2025	27	68	68	25	273	TRADE	BEARISH
12:33 PMOct 20, 2025	PUT	$970.00	Sep 18, 2026	328	38	38	Infinity	0	SWEEP	NEUTRAL
11:25 AMOct 20, 2025	CALL	$600.00	Sep 18, 2026	328	103	40	23	447	TRADE	BEARISH
11:16 AMOct 20, 2025	CALL	$600.00	Sep 18, 2026	328	62	60	14	447	TRADE	BEARISH
03:33 PMOct 17, 2025	CALL	$770.00	Oct 31, 2025	6	305	286	28	1087	TRADE	NEUTRAL
03:33 PMOct 17, 2025	CALL	$810.00	Oct 31, 2025	6	312	286	427	73	TRADE	NEUTRAL
03:10 PMOct 17, 2025	CALL	$775.00	Oct 17, 2025	-8	302	300	47	640	TRADE	NEUTRAL
11:53 AMOct 17, 2025	CALL	$220.00	Dec 19, 2025	55	10	10	8	125	TRADE	BEARISH
11:31 AMOct 17, 2025	CALL	$600.00	Sep 18, 2026	328	75	54	20	372	TRADE	BEARISH
09:31 AMOct 17, 2025	CALL	$700.00	Sep 18, 2026	328	50	50	15	337	SWEEP	BULLISH

Comments

Eli Lilly

Unusual Options Activity for

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL